CoChat

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice

Open access
Liang, Bo, Wu, Ling, Xu, Hui, Cheung, Chun Wai, Fung, Wen Ying, Wong, Sze Wai, Wang, Chi Chiu · 2018 · Reproductive Biology and Endocrinology

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied. METHODS: In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored. RESULTS: After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group. CONCLUSION: Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12958-018-0347-9

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Esmya, Duphaston and Dienogest suppress the growth and development of endometriotic lesions in mice. a Lesion size was measured by caliper at the end of intervention. Representative in situ pictures of the endometriotic lesions in vehicle, Esmya, Duphaston and Dienogest group are shown. Red arrows indicate the locations of the lesions. b Endometriotic lesion size and weight. Data are shown as mean ± SEM, n = 9 for each group, *: p < 0.05 when compared to the control group. c Histological change of lesions after medication. This panels show the representative cross-sections of the endometriotic lesion as endometrial cyst-like structure. Scar bar: 400um. d Proliferation of the endometriotic lesions. Representative pictures of immunohistochemical staining of Ki67 in endometriotic-like lesions in different groups after treatment. Scar bar: 200um. e Comparison of Ki67 positively stained epithelial and stroma cells in the lesions. f Representative pictures of TUNEL staining in endometriotic-like lesions in different groups after treatment. Scar bar: 200um. g Comparison of TUNEL positively cells in the lesions. Data are shown as mean ± SEM, n = 3 for each group, *: p < 0.05 when compared to the control group
Fig. 1 Esmya, Duphaston and Dienogest suppress the growth and development of endometriotic lesions in mice. a Lesion size was measured by caliper at the end of intervention. Representative in situ pictures of the endometriotic lesions in vehicle, Esmya, Duphaston and Dienogest group are shown. Red arrows indicate the locations of the lesions. b Endometriotic lesion size and weight. Data are shown as mean ± SEM, n = 9 for each group, *: p < 0.05 when compared to the control group. c Histological change of lesions after medication. This panels show the representative cross-sections of the endometriotic lesion as endometrial cyst-like structure. Scar bar: 400um. d Proliferation of the endometriotic lesions. Representative pictures of immunohistochemical staining of Ki67 in endometriotic-like lesions in different groups after treatment. Scar bar: 200um. e Comparison of Ki67 positively stained epithelial and stroma cells in the lesions. f Representative pictures of TUNEL staining in endometriotic-like lesions in different groups after treatment. Scar bar: 200um. g Comparison of TUNEL positively cells in the lesions. Data are shown as mean ± SEM, n = 3 for each group, *: p < 0.05 when compared to the control groupCC BY · PubMed Central
Fig. 2 Comparisons of anti-endometriosis mechanism of Esmya, Duphaston and Dienogest. Relative mRNA expression of a-c, adhesion (Mmp2 and Itgav β3) and invasion (Plau) marker genes, d-f, apoptosis-related genes (Mapk1, NF-kB p105 and pro-Caspase 3), g-i, angiogenesis and proliferation mrakers (Vegf, Hif1α and Pcna) and j-k, hormone receptors (ERα/ERβ ratio and PR) in lesions; and ELISA quantitation of l, Prostaglandin E2 (PGE2) concentrations in peritoneal fluid. Data are shown as mean ± SEM, n = 9 for each group, *: p < 0.05 when compared to the control group
Fig. 2 Comparisons of anti-endometriosis mechanism of Esmya, Duphaston and Dienogest. Relative mRNA expression of a-c, adhesion (Mmp2 and Itgav β3) and invasion (Plau) marker genes, d-f, apoptosis-related genes (Mapk1, NF-kB p105 and pro-Caspase 3), g-i, angiogenesis and proliferation mrakers (Vegf, Hif1α and Pcna) and j-k, hormone receptors (ERα/ERβ ratio and PR) in lesions; and ELISA quantitation of l, Prostaglandin E2 (PGE2) concentrations in peritoneal fluid. Data are shown as mean ± SEM, n = 9 for each group, *: p < 0.05 when compared to the control groupCC BY · PubMed Central
Fig. 3 Safety profiles of Esmya, Duphaston and Dienogest. a Body weight changes during the study intervention. Data was recorded every 5 days from day 1 to day 25 after transplantation. b Serum estrogen and progesterone concentrations after treatment in the mice. c Upper panels show the representative cross section images of uterus, structure of endometrium gland, stroma and lumen cavity. Scar bar: 200um. Lower panels compare the uterus size, ratio of uterus and body weight, endometrium thickness index (ETI) and uterus gland count from left to right. d Upper panels show the histological change of ovary after treatment. Scar bar: 200um. Lower panels compared the ovary size, ratio of ovary and body weight and the follicle count from left to right. Data are shown as mean ± SEM. *: p < 0.05 when compared to the control group
Fig. 3 Safety profiles of Esmya, Duphaston and Dienogest. a Body weight changes during the study intervention. Data was recorded every 5 days from day 1 to day 25 after transplantation. b Serum estrogen and progesterone concentrations after treatment in the mice. c Upper panels show the representative cross section images of uterus, structure of endometrium gland, stroma and lumen cavity. Scar bar: 200um. Lower panels compare the uterus size, ratio of uterus and body weight, endometrium thickness index (ETI) and uterus gland count from left to right. d Upper panels show the histological change of ovary after treatment. Scar bar: 200um. Lower panels compared the ovary size, ratio of ovary and body weight and the follicle count from left to right. Data are shown as mean ± SEM. *: p < 0.05 when compared to the control groupCC BY · PubMed Central
Fig. 4 Dynamic change of endometriotic lesion size during and after treatment of Esmya, Duphaston and Dienogest. The endometriotic lesions were transplanted subcutaneously in day − 7. Intervention was started at day 0 and withdrawn at day 21 (yellow dot line). Data were shown as mean ± SEM, n = 10 for each group, *: p < 0.05 when compared to the control group in the corresponding days and groups
Fig. 4 Dynamic change of endometriotic lesion size during and after treatment of Esmya, Duphaston and Dienogest. The endometriotic lesions were transplanted subcutaneously in day − 7. Intervention was started at day 0 and withdrawn at day 21 (yellow dot line). Data were shown as mean ± SEM, n = 10 for each group, *: p < 0.05 when compared to the control group in the corresponding days and groupsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 1

  1. Rockville. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: Center for Drug Evaluation and Research (CDER); 2005.

Cited by

See all 47

Metadata

Authors
Liang, B., Wu, L., Xu, H., Cheung, C. W., Fung, W. Y., Wong, S. W., & Wang, C. C.
Affiliations
Chinese University of Hong Kong (HK)
Corresponding author
Wang, Chi Chiu
Venue
Reproductive Biology and Endocrinology
Published
2018-04-03
Volume
16
Issue
1
Pages
32-32
ISSN
1477-7827 (ISSN-L)
OpenAlex
W2796429112
Cited by
41
References
80
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 14 · 2020: 4 · 2019: 4 · 2018: 1
FWCI
6.13
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Reproductive Biology and Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
endometriosis, progestins, selective progesterone receptor modulators, dienogest, endometriosis recurrence, endometriotic lesion growth, apoptosis, cell proliferation, adhesion molecules, follicle count, mouse model of endometriosis
MeSH terms
Animals, Atrophy, Dydrogesterone, Endometrial Hyperplasia, Endometriosis, Endometrium, Female, Mice, Inbred C57BL, Nandrolone, Norpregnadienes, Progestins, Receptors, Progesterone, Recurrence, Apoptosis, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. https://app.cochat.ai/papers/10.1186/s12958-018-0347-9
The paper
Liang, B., Wu, L., Xu, H., Cheung, C. W., Fung, W. Y., Wong, S. W., & Wang, C. C. (2018). Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-018-0347-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.